RESEARCH MONOGRAPH · KDC-MN-146

N-Acetyl-L-Tyrosine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

59/100

The acetylated version is marketed as more bioavailable than tyrosine and the data dont really support that

N-Acetyl-L-Tyrosine is one of those compounds that gets sold based on a marketing claim that the underlying pharmacokinetics dont quite support. The claim is that acetylation improves solubility and bioavailability for delivering tyrosine across the blood-brain barrier. The reality is more complicated.

Acetylation does improve aqueous solubility, which matters for some formulation contexts. But the relevant pharmacokinetic step for getting tyrosine into the brain isnt solubility, it's the LAT1 transporter at the blood-brain barrier which transports L-tyrosine (not N-acetyl-tyrosine) using the large neutral amino acid system. N-acetyl-tyrosine is largely deacetylated in plasma to free tyrosine plus acetate, and Yokogoshi's work and others have shown that the resulting plasma tyrosine elevation from oral N-acetyl-tyrosine is actually lower per gram than from oral L-tyrosine itself, because some of the N-acetyl-tyrosine is cleared renally as the intact acetylated form before deacetylation completes.

So you end up with less tyrosine in plasma per gram administered, not more. The marketing claim that N-acetyl-tyrosine is a more efficient delivery vehicle gets the pharmacology backward.

What we like: it does dissolve in water better than L-tyrosine, which can matter for certain experimental delivery contexts. And the acetylation does protect against some forms of oxidative degradation during storage.

What we dont like: it's worse at delivering tyrosine to the brain than free tyrosine, which is the actual reason most people are taking it. The marketing-versus-pharmacology mismatch is the main issue.

Mechanism: deacetylation in plasma releases free tyrosine, which then competes with other LNAAs for LAT1-mediated brain entry. The acetylated form itself doesnt cross efficiently and doesnt have intrinsic activity.

Sourcing: synthesized from tyrosine by acetylation, easy to make, easy to verify. Quality from research-grade suppliers is fine.

Overhyped relative to L-tyrosine itself. Not bad, just unnecessary in most contexts. If you want catecholamine precursor delivery, free L-tyrosine is more efficient per gram and cheaper. The N-acetyl version only makes sense in very specific formulation contexts that require enhanced aqueous solubility.

Evidence: 40
Mechanism: 75
Reliability: 55
Safety: 85
Sourcing: 80
Value: 50
Signal: 45
Staying power: 45

Plain-language summary Intrigue 42 / 100

N-acetyl-L-tyrosine (NALT) is the acetylated form of tyrosine, marketed as more bioavailable than free tyrosine. Evidence for the bioavailability claim is limited but the compound is widely used in nootropic formulations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Acetylated tyrosine

An N-acetylated form of L-tyrosine with claimed superior bioavailability that has not been validated in pharmacokinetic studies.

Abstract

N-Acetyl-L-Tyrosine (NALT) is an N-acetylated form of L-tyrosine sold as a dietary supplement with claims of improved bioavailability and CNS penetration compared with L-tyrosine itself. Pharmacokinetic studies in humans show that NALT is poorly converted to free tyrosine by tissue deacetylases (the bulk is excreted as NALT in urine without contributing to tyrosine pools). The compound is therefore likely to be inferior to L-tyrosine on a milligram basis for catecholamine support applications, despite vendor claims. Investigators should generally use L-tyrosine itself.

Mechanism of action

N-acetylated tyrosine; poorly deacetylated in vivo. Bioavailability claims not validated.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Hoffer LJ, et al. Pharmacokinetics of NALT compared with L-tyrosine. Studies show poor in vivo deacetylation.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-146

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

N-Acetyl-L-Tyrosine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs